|Bid||11.25 x 1200|
|Ask||11.84 x 1800|
|Day's range||11.36 - 11.87|
|52-week range||11.36 - 39.12|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.
We can readily understand why investors are attracted to unprofitable companies. For example, although...